Copyright
©The Author(s) 2025.
World J Nephrol. Jun 25, 2025; 14(2): 100117
Published online Jun 25, 2025. doi: 10.5527/wjn.v14.i2.100117
Published online Jun 25, 2025. doi: 10.5527/wjn.v14.i2.100117
Table 2 Comparison of serum phosphorus response to baseline phosphorus at each visit (n = 94)
Visit | mean ± SD | P value (compared to baseline) |
Serum phosphorus (mg/dL) | ||
Per protocol population (n = 94) | ||
Screening visit: Day 7 to Day 1 | 7.62 ± 2.02 | - |
Follow-up visit: Day 28 | 6.37 ± 2.33 | P < 0.05 |
Follow-up visit: Day 56 | 5.49 ± 2.19 | P < 0.05 |
End of study visit: Day 84 | 5.13 ± 1.88 | P < 0.05 |
Change from baseline at Day 28 | 1.25 ± 1.55 | P < 0.05 |
Change from baseline at Day 56 | 2.19 ± 2.07 | P < 0.05 |
Change from baseline at Day 84 | 2.49 ± 2.13 | P < 0.05 |
- Citation: Niranjan MR, Srinivasa S, Gupta V, Bhalla AK, Gaikwad A, Wangikar P, Suryawanshi S, Gajbe P. Sucroferric oxyhydroxide monotherapy for hyperphosphatemia in Indian chronic kidney disease patients undergoing hemodialysis: A phase IV, single-arm, open-label study. World J Nephrol 2025; 14(2): 100117
- URL: https://www.wjgnet.com/2220-6124/full/v14/i2/100117.htm
- DOI: https://dx.doi.org/10.5527/wjn.v14.i2.100117